|19th November 2020||John Purpura||1,600||Open or private purchase||$12.68||$20,288.00|
|17th November 2020||Steven A J Salamon||2,500||Open or private purchase||$12.11||$30,280.00|
|17th November 2020||Advisors, Inc. Rosalind||2,500||Open or private purchase||$12.11||$30,280.00|
|16th November 2020||Gil Aharon||2,000||Open or private purchase||$12.00||$24,000.00|
|13th November 2020||Steven A J Salamon||2,000||Open or private purchase||$11.51||$23,020.00|
|13th November 2020||Advisors, Inc. Rosalind||4,000||Open or private purchase||$11.75||$47,000.00|
|10th September 2020||Jennifer K. Simpson||1,000||Open or private purchase||$2.74||$2,737.10|
|1st September 2020||Jennifer K. Simpson||2,424||Open or private purchase||$0.00|
|8th May 2020||Jennifer K. Simpson||14,700||Conversion of derivative||$0.00|
|8th May 2020||John Purpura||6,500||Conversion of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection.